{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:42:41Z","timestamp":1789609361174,"version":"build-2803163510"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"1073","license":[{"start":{"date-parts":[[2015,2,6]],"date-time":"2015-02-06T00:00:00Z","timestamp":1423180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,3,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Hypersensitivity reactions to chemotherapy drugs pose significant difficulties in management, especially when no suitable alternative is available or acceptable and delay in continuation of treatment may be life-threatening. Such reactions may be IgE- or non-IgE-mediated and have varied manifestations. Timely recognition and treatment of life-threatening hypersensitivity reactions are essential. Identification of patients at high risk of developing hypersensitivity reactions allows risk stratification to guide clinical decision-making. Skin testing for carboplatin hypersensitivity has good predictive value but is not yet established for oxaliplatin and taxane hypersensitivity. Rapid desensitisation may be considered if no suitable alternative drug is available. Available protocols have shown good safety and efficacy but must be performed in an appropriate setting with adequate monitoring. There are many avenues for research into the utility of skin testing for other chemotherapy agents as well as in vitro tests.<\/jats:p>","DOI":"10.1136\/postgradmedj-2014-132686","type":"journal-article","created":{"date-parts":[[2015,2,7]],"date-time":"2015-02-07T05:02:12Z","timestamp":1423285332000},"page":"145-150","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Evaluation and management of hypersensitivity reactions to chemotherapy agents"],"prefix":"10.1093","volume":"91","author":[{"given":"Elizabeth Huiwen","family":"Tham","sequence":"first","affiliation":[{"name":"University Children's Medical Institute, National University Hospital , Singapore, Singapore"},{"name":"Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore , Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yew Kuang","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Allergy, Arthritis & Rheumatism Clinic, Gleneagles Medical Centre , Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miah Hiang","family":"Tay","sequence":"additional","affiliation":[{"name":"Oncocare Clinic, Gleneagles Medical Centre , Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Patricia","family":"Alcasabas","sequence":"additional","affiliation":[{"name":"University Children's Medical Institute, National University Hospital , Singapore, Singapore"},{"name":"Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore , Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette Pei-Chi","family":"Shek","sequence":"additional","affiliation":[{"name":"University Children's Medical Institute, National University Hospital , Singapore, Singapore"},{"name":"Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore , Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,2,6]]},"reference":[{"key":"2023041905283152600_R1","first-page":"635","article-title":"Pneumonitis related to docetaxel: case report and review of the literature","volume":"23","author":"Alsamarai","year":"2009","journal-title":"In Vivo"},{"key":"2023041905283152600_R2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/ijgc-00009577-200501000-00003","article-title":"Carboplatin hypersensitivity","volume":"15","author":"Sliesoraitis","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"2023041905283152600_R3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s101470200056","article-title":"Anaphylaxis to cisplatin following nine previous uncomplicated cycles","volume":"7","author":"Basu","year":"2002","journal-title":"Int J Clin Oncol"},{"key":"2023041905283152600_R4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-3-12","article-title":"Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature","volume":"3","author":"Bautista","year":"2010","journal-title":"J Hematol Oncol"},{"key":"2023041905283152600_R5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/oxfordjournals.annonc.a058776","article-title":"Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"5","author":"Mertens","year":"1994","journal-title":"Ann Oncol"},{"key":"2023041905283152600_R6","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","article-title":"Paclitaxel (taxol)","volume":"332","author":"Rowinsky","year":"1995","journal-title":"N Engl J Med"},{"key":"2023041905283152600_R7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/oxfordjournals.annonc.a058599","article-title":"Coping with toxicities of docetaxel (Taxotere)","volume":"4","author":"Schrijvers","year":"1993","journal-title":"Ann Oncol"},{"key":"2023041905283152600_R8","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ygyno.2004.11.043","article-title":"Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments","volume":"96","author":"Feldweg","year":"2005","journal-title":"Gynecol Oncol"},{"key":"2023041905283152600_R9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2500\/108854197778590506","article-title":"Update on mast cells and mast cell precursors and hypersensitivity responses","volume":"18","author":"Castells","year":"1997","journal-title":"Allergy Asthma Proc"},{"key":"2023041905283152600_R10","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1567-5769(01)00006-6","article-title":"Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions","volume":"1","author":"Szebeni","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"2023041905283152600_R11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaip.2013.08.011","article-title":"Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization","volume":"2","author":"Wong","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2023041905283152600_R12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1023\/A:1008336108007","article-title":"Immunohemolytic anemia following oxaliplatin administration","volume":"11","author":"Garufi","year":"2000","journal-title":"Ann Oncol"},{"key":"2023041905283152600_R13","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/annonc\/mdl116","article-title":"Serious delayed hypersensitivity reaction to oxaliplatin","volume":"17","author":"de Vries","year":"2006","journal-title":"Ann Oncol"},{"key":"2023041905283152600_R14","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","article-title":"Hypersensitivity reactions from taxol","volume":"8","author":"Weiss","year":"1990","journal-title":"J Clin Oncol"},{"key":"2023041905283152600_R15","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.162.11.6811","article-title":"Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide","volume":"162","author":"Mullins","year":"1999","journal-title":"J Immunol"},{"key":"2023041905283152600_R16","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1200\/JCO.1993.11.5.885","article-title":"Successful re-treatment with taxol after major hypersensitivity reactions","volume":"11","author":"Peereboom","year":"1993","journal-title":"J Clin Oncol"},{"key":"2023041905283152600_R17","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2165\/00002018-200124100-00005","article-title":"Prevention and management of antineoplastic-induced hypersensitivity reactions","volume":"24","author":"Zanotti","year":"2001","journal-title":"Drug Saf"},{"key":"2023041905283152600_R18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jnci\/90.4.300","article-title":"Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study","volume":"90","author":"Szebeni","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"2023041905283152600_R19","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ejps.2011.09.016","article-title":"Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20","volume":"45","author":"Weiszhar","year":"2012","journal-title":"Eur J Pharm Sci"},{"key":"2023041905283152600_R20","first-page":"170","article-title":"Immunoglobulin E-mediated severe anaphylaxis to paclitaxel","volume":"20","author":"Prieto Garcia","year":"2010","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2023041905283152600_R21","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/all.12105","article-title":"Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment","volume":"68","author":"Madrigal-Burgaleta","year":"2013","journal-title":"Allergy"},{"key":"2023041905283152600_R22","first-page":"108","article-title":"A new rapid desensitization protocol for chemotherapy agents","volume":"21","author":"Gastaminza","year":"2011","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2023041905283152600_R23","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","article-title":"Clinical features of hypersensitivity reactions to carboplatin","volume":"17","author":"Markman","year":"1999","journal-title":"J Clin Oncol"},{"key":"2023041905283152600_R24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2006.10.047","article-title":"Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants\u2019 Hospital","volume":"105","author":"Schwartz","year":"2007","journal-title":"Gynecol Oncol"},{"key":"2023041905283152600_R25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1385\/CRIAI:24:3:253","article-title":"Hypersensitivity reactions to chemotherapeutic drugs","volume":"24","author":"Shepherd","year":"2003","journal-title":"Clin Rev Allergy Immunol"},{"key":"2023041905283152600_R26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00280-004-0924-9","article-title":"Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy","volume":"56","author":"Sendo","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"2023041905283152600_R27","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jaci.2009.02.042","article-title":"Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management","volume":"123","author":"Hesterberg","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"2023041905283152600_R28","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2001.19.12.3126","article-title":"Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy","volume":"19","author":"Zanotti","year":"2001","journal-title":"J Clin Oncol"},{"key":"2023041905283152600_R29","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1200\/JCO.2003.05.539","article-title":"Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity","volume":"21","author":"Markman","year":"2003","journal-title":"J Clin Oncol"},{"key":"2023041905283152600_R30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000107467","article-title":"Standardization of skin tests for diagnosis and prevention of hypersensitivity reactions to oxaliplatin","volume":"145","author":"Pagani","year":"2008","journal-title":"Int Arch Allergy Immunol"},{"key":"2023041905283152600_R31","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/annonc\/mdg092","article-title":"Skin testing and hypersensitivity reactions to oxaliplatin","volume":"14","author":"Garufi","year":"2003","journal-title":"Ann Oncol"},{"key":"2023041905283152600_R32","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.2002.20.4.1146","article-title":"Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule","volume":"20","author":"Meyer","year":"2002","journal-title":"J Clin Oncol"},{"key":"2023041905283152600_R33","first-page":"494","article-title":"Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy","volume":"1","author":"Caiado","year":"2013"},{"key":"2023041905283152600_R34","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jaci.2006.11.640","article-title":"Diagnostic and predictive value of skin testing in platinum salt hypersensitivity","volume":"119","author":"Leguy-Seguin","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"2023041905283152600_R35","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","article-title":"Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases","volume":"122","author":"Castells","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"2023041905283152600_R36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1939-4551-7-9","article-title":"International consensus on (ICON) anaphylaxis","volume":"7","author":"Simons","year":"2014","journal-title":"World Allergy Organ J"},{"key":"2023041905283152600_R37","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/all.12437","article-title":"Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology","volume":"69","author":"Muraro","year":"2014","journal-title":"Allergy"},{"key":"2023041905283152600_R38","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2005.06.028","article-title":"Rapid inpatient\/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses","volume":"99","author":"Lee","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"(1 Suppl)","key":"2023041905283152600_R39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1188\/07.CJON.S1.37-42","article-title":"Cytokine-release syndrome: overview and nursing implications","volume":"11","author":"Breslin","year":"2007","journal-title":"Clin J Oncol Nurs"},{"key":"2023041905283152600_R40","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2000.18.1.102","article-title":"Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center","volume":"18","author":"Markman","year":"2000","journal-title":"J Clin Oncol"},{"key":"2023041905283152600_R41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000055363","article-title":"Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience","volume":"61","author":"Polyzos","year":"2001","journal-title":"Oncology"},{"key":"2023041905283152600_R42","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1006\/gyno.2001.6519","article-title":"Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy","volume":"84","author":"Dizon","year":"2002","journal-title":"Gynecol Oncol"},{"key":"2023041905283152600_R43","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.bjc.6601155","article-title":"Hypersensitivity reactions related to oxaliplatin (OHP)","volume":"89","author":"Brandi","year":"2003","journal-title":"Br J Cancer"},{"key":"2023041905283152600_R44","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1200\/JCO.1996.14.2.422","article-title":"Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group","volume":"14","author":"Trudeau","year":"1996","journal-title":"J Clin Oncol"},{"key":"2023041905283152600_R45","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/oxfordjournals.annonc.a010806","article-title":"Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel","volume":"7","author":"Gennari","year":"1996","journal-title":"Ann Oncol"},{"key":"2023041905283152600_R46","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.1997.15.12.3517","article-title":"Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions","volume":"15","author":"Markman","year":"1997","journal-title":"J Clin Oncol"},{"key":"2023041905283152600_R47","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/028418602320404998","article-title":"Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum","volume":"41","author":"Rosenberg","year":"2002","journal-title":"Acta Oncol"},{"key":"2023041905283152600_R48","doi-asserted-by":"crossref","DOI":"10.1177\/1078155210367950","article-title":"Single premedication dose of dexamethasone 20\u2005mg IV before docetaxel administration","volume":"17","author":"Chouhan","year":"2011","journal-title":"J Oncol Pharm Pract"},{"key":"2023041905283152600_R49","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000324454","article-title":"Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol","volume":"156","author":"Syrigou","year":"2011","journal-title":"Int Arch Allergy Immunol"},{"key":"2023041905283152600_R50","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/jjco\/hys006","article-title":"An experimental biological test to diagnose hypersensitivity reactions to carboplatin: new horizons for an old problem","volume":"42","author":"Pagani","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"2023041905283152600_R51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000087355","article-title":"Antigen-induced reduction in mast cell and basophil functional responses due to reduced Syk protein levels","volume":"138","author":"Kepley","year":"2005","journal-title":"Int Arch Allergy Immunol"},{"key":"2023041905283152600_R52","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1365-2222.1995.tb00033.x","article-title":"Challenge of mast cells with increasing amounts of antigen induces desensitization","volume":"25","author":"Shalit","year":"1995","journal-title":"Clin Exp Allergy"},{"key":"2023041905283152600_R53","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1111\/j.1365-2222.2011.03825.x","article-title":"Desensitization regimens for drug allergy: state of the art in the 21st century","volume":"41","author":"Liu","year":"2011","journal-title":"Clin Exp Allergy"},{"key":"2023041905283152600_R54","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1046\/j.1525-1438.1999.99014.x","article-title":"Effective desensitization protocol to paclitaxel following hypersensitivity reaction","volume":"9","author":"Fishman","year":"1999","journal-title":"Int J Gynecol Cancer"},{"issue":"(1 Pt 1)","key":"2023041905283152600_R55","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0091-6749(96)70281-6","article-title":"Successful parenteral desensitization to paclitaxel","volume":"97","author":"Essayan","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"2023041905283152600_R56","first-page":"7","article-title":"Second symposium on the definition and management of anaphylaxis: summary report\u2014Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"117","author":"Sampson","year":"2006","journal-title":"Ann Emerg Med"},{"key":"2023041905283152600_R57","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaci.2009.08.027","article-title":"Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity","volume":"124","author":"Rueff","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"2023041905283152600_R58","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1081-1206(10)60247-5","article-title":"Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization","volume":"102","author":"Breslow","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2023041905283152600_R59","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.anai.2010.08.002","article-title":"Drug allergy: an updated practice parameter","volume":"105","author":"Joint Task Force on Practice P, American Academy of Allergy A, Immunology","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2023041905283152600_R60","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00431-010-1236-1","article-title":"Clinical practice: drug desensitization in children","volume":"169","author":"de Groot","year":"2010","journal-title":"Eur J Pediatr"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/91\/1073\/145\/50002358\/postgradmedj-91-145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/91\/1073\/145\/50002358\/postgradmedj-91-145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T05:30:43Z","timestamp":1681882243000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/91\/1073\/145\/6993872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,6]]},"references-count":60,"journal-issue":{"issue":"1073","published-online":{"date-parts":[[2015,2,6]]},"published-print":{"date-parts":[[2015,3,1]]}},"URL":"https:\/\/doi.org\/10.1136\/postgradmedj-2014-132686","relation":{},"ISSN":["1469-0756","0032-5473"],"issn-type":[{"value":"1469-0756","type":"electronic"},{"value":"0032-5473","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,3]]},"published":{"date-parts":[[2015,2,6]]}}}